<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00457236</url>
  </required_header>
  <id_info>
    <org_study_id>HZ-BK-2003-1</org_study_id>
    <nct_id>NCT00457236</nct_id>
  </id_info>
  <brief_title>Effect of Clopidogrel Loading and Risk of PCI</brief_title>
  <acronym>EXCELSIOR</acronym>
  <official_title>Impact of the Degree of Peri-Interventional Platelet Inhibition After Loading With Clopidogrel on Early Clinical Outcome of Elective Coronary Stent Placement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Heart Center Freiburg - Bad Krozingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Heart Center Freiburg - Bad Krozingen</source>
  <brief_summary>
    <textblock>
      This study is a prospective, single-center evaluation of the impact of the variability in&#xD;
      platelet response after loading with clopidogrel on the peri-interventional risk of patients&#xD;
      undergoing PCI.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Platelet responses after loading with clopidogrel are highly variable. The impact&#xD;
      of this variability on the peri-interventional risk of patients undergoing PCI has not been&#xD;
      investigated prospectively.&#xD;
&#xD;
      Objectives: Our prospective study test the hypothesis that the 30-day clinical outcome of&#xD;
      elective percutaneous catheter intervention (PCI) differs between strata defined by quartiles&#xD;
      of platelet aggregation after loading with 600mg of clopidogrel. Further on we will&#xD;
      investigate impact of the variability in platelet response on long-term outcome after PCI.&#xD;
&#xD;
      Methods: Our study will include consecutive patients undergoing elective coronary stent&#xD;
      placement. Before PCI, patients receive a loading dose of 600mg of clopidogrel followed by&#xD;
      75mg daily. Primary end point is the 30-day composite of death, myocardial infarction and&#xD;
      target lesion revascularization (MACE). Platelet aggregation was assessed immediately before&#xD;
      PCI by optical aggregometry (5µmol/L ADP).&#xD;
&#xD;
      Sample size calculation was based on ISAR-REACT which comprised a cohort with similar&#xD;
      selection criteria and treatment strategy. Thus, we assume an incidence of the primary end&#xD;
      point of 4.2%. We design our study to test the hypothesis that the incidence of the primary&#xD;
      end point differed by quartiles of ADP-induced platelet aggregation. We intend to have a&#xD;
      power of 0.80 to detect an effect size of 0.015 (for example 3-fold risk in 4th quartile)&#xD;
      with a 2-sided P-value less than 0.05. With these assumptions we obtain a sample size of at&#xD;
      least 748 and aime for a cohort of 800.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2003</start_date>
  <completion_date type="Anticipated">December 2007</completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Defined Population</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <enrollment>800</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Drug Resistance</condition>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing elective coronary stenting&#xD;
&#xD;
          -  Pretreatment with a bolus dose of 600mg of clopidogrel prior to coronary stent&#xD;
             implantation&#xD;
&#xD;
          -  Pretreatment with aspirin ≥ 100 mg per day for at least 7 days&#xD;
&#xD;
          -  Age &gt; 18 years&#xD;
&#xD;
          -  Written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Troponin T on admission &gt; 0.03 ng/mL&#xD;
&#xD;
          -  Myocardial infarction or fibrinolytic therapy within the previous 14 days&#xD;
&#xD;
          -  Cardiogenic shock&#xD;
&#xD;
          -  Contraindication for aspirin or clopidogrel&#xD;
&#xD;
          -  Oral anticoagulation&#xD;
&#xD;
          -  Pretreatment with heparin or a thienopyridine within the previous 14 days&#xD;
&#xD;
          -  Use of a GP IIb/IIIa-receptor antagonist during PCI&#xD;
&#xD;
          -  Platelet count &lt; 100.000/µl&#xD;
&#xD;
          -  Severe disorders of the coagulation system&#xD;
&#xD;
          -  Severe impairment of liver or kidney function&#xD;
&#xD;
          -  Cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franz-Josef Neumann, MD</last_name>
    <role>Study Director</role>
    <affiliation>Heart Center Bad Krozingen, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Heart Center Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Hochholzer W, Trenk D, Bestehorn HP, Fischer B, Valina CM, Ferenc M, Gick M, Caputo A, Büttner HJ, Neumann FJ. Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol. 2006 Nov 7;48(9):1742-50. Epub 2006 Oct 17.</citation>
    <PMID>17084243</PMID>
  </results_reference>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>April 4, 2007</study_first_submitted>
  <study_first_submitted_qc>April 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2007</study_first_posted>
  <last_update_submitted>April 5, 2007</last_update_submitted>
  <last_update_submitted_qc>April 5, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2007</last_update_posted>
  <keyword>Clopidogrel</keyword>
  <keyword>Coronary Artery Disease</keyword>
  <keyword>Dose-Response Relationship, Drug</keyword>
  <keyword>Drug Resistance</keyword>
  <keyword>PCI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

